Aclaris Therapeutics Inc. Expected to Post FY2018 Earnings of ($2.65) Per Share (ACRS)
Aclaris Therapeutics Inc. (NASDAQ:ACRS) – Investment analysts at Jefferies Group reduced their FY2018 earnings estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday. Jefferies Group analyst D. Steinberg now forecasts that the brokerage will earn ($2.65) per share for the year, down from their prior forecast of ($2.33). Jefferies Group currently has a “Buy” rating and a $31.00 price target on the stock. Jefferies Group also issued estimates for Aclaris Therapeutics’ FY2019 earnings at $0.44 EPS and FY2020 earnings at $2.44 EPS.
A number of other research firms have also commented on ACRS. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 23rd. Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Friday, June 10th. They set a “buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Aclaris Therapeutics currently has an average rating of “Buy” and an average target price of $31.25.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 1.27% during midday trading on Wednesday, hitting $24.81. The stock had a trading volume of 14,557 shares. Aclaris Therapeutics has a 52 week low of $10.99 and a 52 week high of $33.88. The stock’s market capitalization is $531.31 million. The stock has a 50 day moving average price of $21.21 and a 200-day moving average price of $19.73.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.01.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its position in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock worth $106,000 after buying an additional 1,838 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock worth $536,000 after buying an additional 5,535 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Aclaris Therapeutics by 18.3% in the first quarter. Geode Capital Management LLC now owns 43,246 shares of the company’s stock worth $819,000 after buying an additional 6,679 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Aclaris Therapeutics by 54.7% in the second quarter. California State Teachers Retirement System now owns 18,896 shares of the company’s stock worth $349,000 after buying an additional 6,683 shares during the last quarter. Finally, Geduld E E raised its position in shares of Aclaris Therapeutics by 62.5% in the second quarter. Geduld E E now owns 17,500 shares of the company’s stock worth $323,000 after buying an additional 6,729 shares during the last quarter. Hedge funds and other institutional investors own 71.39% of the company’s stock.
In other Aclaris Therapeutics news, major shareholder Ra Capital Management, Llc sold 525,550 shares of the stock in a transaction on Friday, September 16th. The stock was sold at an average price of $24.19, for a total value of $12,713,054.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kamil Ali-Jackson sold 3,738 shares of the stock in a transaction on Friday, August 26th. The shares were sold at an average price of $20.35, for a total value of $76,068.30. Following the completion of the transaction, the insider now owns 20,289 shares in the company, valued at $412,881.15. The disclosure for this sale can be found here. 46.40% of the stock is owned by company insiders.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.